Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Grows By 62.3%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 27,101 shares, an increase of 62.3% from the December 15th total of 16,694 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 14,747 shares, the days-to-cover ratio is currently 1.8 days. Based on an average daily volume of 14,747 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.7% of the company’s shares are short sold.

vTv Therapeutics Trading Down 4.5%

Shares of VTVT stock opened at $35.59 on Friday. The firm’s fifty day moving average price is $33.66 and its two-hundred day moving average price is $23.98. vTv Therapeutics has a 1 year low of $13.46 and a 1 year high of $44.00. The firm has a market capitalization of $140.15 million, a P/E ratio of -10.72 and a beta of 0.48.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VTVT. TD Cowen initiated coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating and a $67.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $47.00 target price (up previously from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. BTIG Research started coverage on vTv Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Cowen began coverage on vTv Therapeutics in a research note on Monday, January 5th. They set a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, vTv Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $51.33.

Institutional Investors Weigh In On vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP increased its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.